Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

Additional studies are needed to further evaluate PH-762's safety and efficacy.

Rhea-AI Summary

Phio Pharmaceuticals (PHIO) presented final Phase 1b clinical results for PH-762 at the American Society for Dermatologic Surgery annual meeting. The meeting took place November 5-8, 2026, in San Diego, California.

The study assessed PH-762 injected into tumors as a treatment before surgery for cutaneous carcinomas, or skin cancers. Findings suggested PH-762 was well-tolerated and may offer a tissue-sparing treatment before surgery for cutaneous squamous cell carcinoma, alongside the current standard of Mohs micrographic surgery or standard excision. Phio plans a Phase 2b study in the first half of 2027.

Positive

• Minor pointFinal Phase 1b findings suggested PH-762 was well-tolerated and may offer a tissue-sparing treatment before surgery.
• Minor point. Forward-looking: it has not happened yet and may not happen.Phase 2b study is planned for the first half of 2027.

Negative

• None.

Key Figures

Phase 2b study timing: First half of 2027

Phase 2b study timing

First half of 2027

Planned follow-up study of PH-762

Historical Context

1 past event · Latest: Oct 13

1 event

1. Oct 13

   Manufacturing milestone

   24h Move

   +1.4%

   First commercial-scale PH-762 drug-substance batch released for planned Phase 2b trial supply.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

sirna, neoadjuvant, intratumoral injection, cscc

4 terms

sirna medical

"clinical-stage siRNA biopharmaceutical company"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

neoadjuvant medical

"as a neoadjuvant intratumoral injection for cutaneous carcinomas"

"Neoadjuvant" describes treatments or interventions that are given before the main or primary procedure, such as surgery or a major decision. It’s like preparing the ground before planting seeds, aiming to improve the final outcome. For investors, understanding neoadjuvant approaches can provide insight into how companies enhance results or effectiveness in their processes or products.

intratumoral injection medical

"as a neoadjuvant intratumoral injection for cutaneous carcinomas"

An intratumoral injection is a treatment delivered directly into a tumor rather than into the bloodstream or muscle; imagine putting weed killer precisely onto a single weed instead of spraying the whole garden. For investors, this matters because direct delivery can increase a therapy’s effectiveness and reduce systemic side effects, but it can also limit patient eligibility, complicate clinical trials and procedures, and affect commercial scalability and regulatory review.

cscc medical

"the current cSCC treatment standard of MMS and/or standard excision"

Cutaneous squamous cell carcinoma (CSCC) is a common type of skin cancer that starts in the outer layer of the skin, often after long-term sun exposure. It can behave like a weed growing from a small patch—usually treatable when caught early but capable of invading nearby tissue or spreading if unchecked. For investors, CSCC matters because its prevalence and severity drive demand for diagnostics, treatments and follow-on care, influencing clinical trial opportunities, regulatory decisions and market potential in the oncology sector.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical Fatigue

King of Prussia, Pennsylvania--(Newsfile Corp. - November 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS), held in San Diego, California, from November 5-8, 2026.

"The growing body of clinical evidence supporting PH-762 continues to demonstrate its potential to address an important unmet need in the treatment of cutaneous carcinomas," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. "We believe these findings highlight PH-762's potential to become a differentiated, tissue-sparing neoadjuvant therapy that may shrink tumors before surgery, reduce the extent of resection, and ultimately improve patient outcomes."

Phio's e-presentation "Intasyl siRNA Compound PH-762", was presented by John Strasswimmer, M.D., Ph.D., of Florida Atlantic University and Integrity Research at Dermatology Associates of the Palm Beaches, Inc., Delray Beach, Florida. Dr. Strasswimmer served as the lead investigator of the Phase 1b clinical trial.

Highlights of the presentation included final results of the first Phase 1b study assessing the safety and efficacy of INTASYL PH-762 as a neoadjuvant intratumoral injection for cutaneous carcinomas. Study findings suggested PH-762 is well-tolerated and may represent a tissue-sparing neoadjuvant to the current cSCC treatment standard of MMS and/or standard excision. Additional studies are needed to further evaluate the safety and efficacy of PH-762 and a Phase 2b study is planned for the first half of 2027.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL^® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the possibility that our INTASYL^® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to offer patients and physicians a meaningful new treatment option capable of shrinking tumors prior to surgery while maintaining an attractive safety profile, the potential for PH-762 to become a differentiated, tissue-sparing neoadjuvant treatment that may reduce the burden of surgery while preserving favorable clinical outcomes, and our expectation that a Phase 2b study will occur in the first half of 2027, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323016

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Phio's Phase 1b study show for PH-762?

Final findings suggested PH-762 was well-tolerated and may offer a tissue-sparing treatment before surgery for cutaneous squamous cell carcinoma. Additional studies are needed to further evaluate its safety and efficacy.

When does Phio plan a Phase 2b study of PH-762?

Phio plans a Phase 2b study in the first half of 2027.